Physician profile
William E Monaco
NPI 1346683240
$96,710.03
in general payments reported to CMS, 2019-2025
24 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $1,125 · 2021: $3,991 · 2022: $29K · 2023: $12K · 2024: $18K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Consulting Fee: $7,760 · Food and Beverage: $7,016 · Travel and Lodging: $3,430 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,750.00 |
| Consulting Fee | $7,760.00 |
| Food and Beverage | $7,015.74 |
| Travel and Lodging | $3,430.37 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76,319.47 | 2019-2025 | |
| Ucb, INC. | $14,346.77 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,504.19 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $876.30 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $634.22 | 2019-2024 | Taltz |
| Genzyme Corporation | $593.11 | 2019-2025 | |
| Janssen Biotech, INC. | $538.34 | 2024-2025 | Tremfya, Simponi Aria, Remicade |
| E.R. Squibb & Sons, L.L.C. | $336.99 | 2019-2024 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $332.70 | 2021-2025 | Saphnelo |
| Pfizer INC. | $291.96 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $256.63 | 2022-2024 | Acthar |
| Genentech USA, INC. | $125.59 | 2019-2025 | Gazyva |
| Organon LLC | $87.45 | 2022-2024 | Renflexis, Hadlima |
| Novartis Pharmaceuticals Corporation | $74.40 | 2020-2024 | |
| Aurinia Pharma U.S., INC. | $63.50 | 2025 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.47 | 2019-2020 | |
| Radius Health, INC. | $48.17 | 2024-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.11 | 2019-2023 | Cyltezo |
| Horizon Therapeutics Plc | $46.08 | 2022-2023 | Krystexxa |
| Genentech, INC. | $38.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $35.89 | 2019 | |
| Recordati_rare_diseases_inc. | $27.13 | 2023 | Sylvant |
| Sobi, INC | $15.79 | 2021 | |
| Sandoz INC. | $13.77 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Monaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.